<DOC>
	<DOCNO>NCT00128232</DOCNO>
	<brief_summary>Currently , first line treatment acromegaly surgery , order remove adenoma cause overproduction growth hormone lead acromegaly . Octreotide LAR approve treatment acromegaly surgery disease control . This study aim test safety efficacy octreotide LAR acromegalic patient previous treatment acromegaly .</brief_summary>
	<brief_title>Safety Efficacy Octreotide Long Acting Release ( LAR ) Treatment Naïve Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Newly diagnose previously untreated acromegalic patient Lack suppression growth hormone ( GH ) nadir &lt; 1.0 µg/L , oral administration 75g glucose ( oral glucose tolerance test [ OGTT ] ) Insulinlike growth factorI ( IGFI ) level upper limit normal , i.e . 97th percentile ( adjust age gender ) Requires surgery recent significant deterioration visual field neurological sign , relate pituitary tumor mass No evidence pituitary adenoma magnetic resonance imaging ( MRI ) Symptomatic cholelithiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>untreated</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>octreotide LAR</keyword>
</DOC>